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Abstract
Objective: We conducted systematic review to evaluate current evidence of herbal medicines (HMs) for Parkinson’s disease
(PD).
Methods: Along with hand searches, relevant literatures were located from the electronic databases including CENTRAL,
MEDLINE, EMBASE, CINAHL, AMED, PsycInfo, CNKI, 7 Korean Medical Databases and J-East until August, 2010 without
language and publication status. Randomized controlled trials (RCTs), quasi-randomized controlled trials and randomized
crossover trials, which evaluate HMs for idiopathic PD were selected for this review. Two independent authors extracted
data from the relevant literatures and any disagreement was solved by discussion.
Results: From the 3432 of relevant literatures, 64 were included. We failed to suggest overall estimates of treatment effects
on PD because of the wide heterogeneity of used herbal recipes and study designs in the included studies. When compared
with placebo, specific effects were not observed in favor of HMs definitely. Direct comparison with conventional drugs
suggested that there was no evidence of better effect for HMs. Many studies compared combination therapy with single
active drugs and combination therapy showed significant improvement in PD related outcomes and decrease in the dose of
anti-Parkinson’s drugs with low adverse events rate.
Conclusion: Currently, there is no conclusive evidence about the effectiveness and efficacy of HMs on PD. For establishing
clinical evidence of HMs on PD, rigorous RCTs with sufficient statistical power should be promoted in future.
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Introduction
Parkinson’s disease (PD) is an age-related neurodegenerative
disorder that pathological feature is basically related on the
progressive degradation of dopamine production in substantia
nigra. The clinical manifestation includes bradykinesia (especially
having difficulties in initiating movement), hypokinesia (lose of
facial expression), rigidity, rest tremor (pill-rolling movement of the
forearm) and non-motor features including depression, psychosis
autonomic dysfunction [1].
Because of diversity of the studies with different population and
methodology, the prevalence rate and incidence varies broadly in
difference studies. In the European countries, crude prevalence
rate estimates ranged from 65.6 per 100,000 to 12,500 per
100,000 and annual incidence estimates ranged from 5 per
100,000 to 26 per 100,000 [2]. On the contrary, prevalence rate
and incidence rate is slightly lower in Asian countries. It was
reported that a standardized all-age prevalence of was 51.3 to
176.9 per 100,000 and the standardized incidence rates were 8.7
per 100,000 person-years [3]. The prevalence increases progres-
sively along with the age. According to the cross-sectional study of
United Kingdom in 2000, the prevalence was only 20/100,000 in
below 50 years old, but 342/100,000 in sixties and 1265/100,000
in over eighties [4]. Considering that medical expenditure for PD
is one of the highest ranked neurologic diseases, PD might be a
serious socioeconomic burden in future aging society [5–7].
Herbal products for PD have been used worldwide in traditional
medicine [8]. Especially in China, records of herbal prescriptions
for treating PD might date back to about 2200 years ago [9] and
current literatures reflect active use of HM for PD until now
[10,11]. Practitioners and patients employ HM as an adjuvant
therapy of conventional treatment for the purpose of reducing
dose of dopaminergic drugs, adverse event related to prolonged
usage of dopaminergic agents and improving PD symptoms [10].
Previous literature reviews have been evaluated the clinical
evidence of HM including traditional Chinese medicine (TCM)
[9,10,12,13]. However these reviews did not adopt explicit search
strategy so all the possible studies might not be located.
Information on the herbal remedies was not presented in details.
In addition, any results on the effect size were not reported. From
these limitations, these reviews failed to suggest the global picture
of HMs for treating PD [9,10,12,13].
The purpose of this review is to evaluate the current evidence
level thorough explicit systematic review method and to present
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HMs for PD patients.
Methods
Types of studies
Randomized controlled trials (RCTs), quasi-randomized con-
trolled trials and randomized crossover trials, which evaluate HMs
for idiopathic PD were included in this review.
Types of participants
Participants of any age and sex with idiopathic PD were
considered to be included. Diagnosis of PD is necessary to be done
considering clinical symptoms and radiological examinations
through the standard diagnostic criteria such as UK Parkinson’s
Disease Brain Bank criteria [14] or the Diagnosis and Differential
Diagnosis of Parkinson’s Disease and Parkinsonism from the
Chinese Colloquium of Extracorticospinal Tract Diseases [15].
Types of intervention
Studies which used HMs as the only intervention or combina-
tion therapy with conventional medicine were included. In this
review, HMs was defined as products originated from botanical
sources such as whole plants or their adjuncts: seed, root, flower,
bud and leaf [16]. In the boundary of HM, low or manufactured
single or complex medicinal plants, plants extracts and plant
preparations for the purpose of treatment were included regardless
of drug preparation: extracts, decoction, tablet, capsule, pill,
powder, injection and etc [17]. However, drugs, which were
consisted of synthesized compounds, were excluded. Complex
intervention with acupuncture, moxibustion and other CAM
treatments was excluded. There is no restriction on dosage
including frequency, dose, intensity and duration. Comparator
interventions were conventional drugs or treatment, surgery,
placebo, usual care or no treatment. Comparison between
different types of HMs was excluded. Conventional drugs include
levodopa (both of the immediate-release and modified-release),
dopamine agonists, monoamine oxidase B inhibitors, catecho-O
methyltransferase inhibitor (COMT) and amatadine etc.
Types of outcome measures
Following primary and secondary outcomes were pre-identified
at the protocol stage:
Primary outcomes. Total Unified Parkinson’s Disease Rat-
ing Scale score (Total UPDRS score)
Global improvement of symptoms
Secondary outcomes. UPDRS I, II, III and IV sub-scores
Webster scale
Hoehn and Yahr (H&Y) staging
Non-movement problems: total non-motor symptoms score
value (NMSQuest), frequency of Nausea & vomiting or constipa-
tion
Mean levodopa or bromocriptine usage
Depression scales: Hamilton depression rating scale (HAM-D)
Quality of life measures: Parkinson’s Disease Questionnaire–39
(PDQ-39) and EuroQol (EQ-5D)
Adverse events rate
Search methods for identification of studies
The following databases were searched until August, 2010. Any
language, document format and date restrictions didn’t included in
the search strategy to minimize possible bias: Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, EM-
BASE, CINAHL (Cumulative Index of Nursing and Allied Health
Medicine), AMED (Allied and Complementary Medicine Data-
base), PsycInfo, China Academic Journal in China National
Knowledge Infrastructure (CNKI), China Doctor/Master’s Dis-
sertation Database in CNKI, China Proceedings of Conference
Database in CNKI, Korean Medical Databases (Korean Studies
Information, DBPIA, Korea Institute of Science and Technology
Information, Research Information Centre for Health Database,
KoreaMed and the Korean National Assembly Library, Korean
traditional knowledge portal) and J-East. Related gray literature
and references of included studies were hand searched. Searching
strategy for medline was as follows:
Medline (Pubmed) search strategy.
#1 Parkinson Disease [mh]
#2 Parkinson$ [tiab]
#3 or/1-2
#4 Medicine, African Traditional [mh]
#5 Medicine, Arabic [mh]
#6 Medicine, Ayurvedic [mh]
#7 Medicine, Kampo [mh]
#8 Medicine, Korean Traditional [mh]
#9 Medicine, Tibetan Traditional [mh]
#10 Medicine, Mongolian Traditional [mh]
#11 Herbal Medicine [mh]
#12 Phytotherapy [mh]
#13 Drugs, Chinese Herbal [mh]
#14 Plants, Medicinal [mh]
#15 Plant Extracts [mh]
#16 Ethnobotany [mh]
#17 Ethnopharmacology [mh]
#18 Plants [mh]
#19 herb$ [tiab]
#20 (Plant Leave$ or Flower$ or Plant Root$ or Fruit$ or
Seed$) [tiab]
#21 or/4-20
#22 3 and 21
#23 randomized controlled trial [pt]
#24 controlled clinical trial [pt]
#25 randomized [tiab]
#26 placebo [tiab]
#27 drug therapy [sh]
#28 randomly [tiab]
#29 groups [tiab]
#30 or/23-29
#31 animals [mh] not (humans [mh] and animals [mh])
#32 30 not 31
Data extraction, risk of bias assessment and analysis
From the included studies, data describing disease duration and
severity, interventions for the treatment and control groups,
summary of the outcomes, last follow up period and recipes of
HMs were extracted according to the pre-defined data extraction
form by two independent authors (THK and WSJ). Any
disagreement between two authors was solved by discussion. Risk
of bias was assessed in 6 domains: random sequence generation,
allocation concealment, blinding of participants, incomplete
outcome data, selective reporting and other bias. Two indepen-
dent authors (THK and KHC) assessed the risk of bias according
to the criteria of Cochrane collaboration [18]. Any conflict was
discussed and there was no disagreement between two authors.
Estimated effect size for each outcome of included HM was
calculated comparing with each control intervention individually.
Individual data were combined for meta-analysis if the studies
adopted the same HM and control intervention. Dichotomous
Herbal Medicines for Parkinson’s Disease
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as mean difference (MD) with 95% CI. Analysis was conducted
with Review manager 5.1 (Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2011).
Results
Description of included studies
Total 3432 of relevant literature were identified from electronic
databases and hand searching. Among them, 64 studies (total 4024
PD patients) were included based on the predefined criteria
(figure 1).
All the included studies were classified into one of four types
according to the trial design: HM versus placebo [19,34], HM
versus conventional medicine [30,43,44,53,57,71,73,77], HM plus
active drug versus active drug [20–23,25–27,29,31–33,35–
38,41,42,45,48–50,52,54,55,56,58–62,64–69,72,74–76,79–82] or
HM plus active drug versus placebo plus active drug
[11,24,28,34,39,40,46,47,51,63,70,78]. Among the 64 studies,
one was conducted in Ecuador [19], another was in UK [24]
and other 62 were in China. All the included studies were RCTs
except two quasi-RCTs [31,54] and one cross-over study [24].
Interventions
A total 59 kinds of herbal preparations were identified in the
included studies (table S1). Among them, several different herbal
recipes which were prescribed individually according to each
patient were used in three studies [80–82]. All the identified
interventions were complex medications which were composed of
three to twenty herbs. Only in two studies, single herbal extracts
were tested [19,24]. In majority of included studies, treatment was
provided during 3 or 6 months (ranging 1 month to 1 year). One
study assessed the short term effect of herbal extract, tested shortly
after taking medication once [19]. Control interventions were
mainly conventional treatment with anti-Parkinson drugs or
Placebo [11,19,24,28,34,39,40,46,47,51,63,70,78]. In 58 trials,
several anti-Parkinson drugs were provided to PD patients,
combined with HMs and 8 studies tested single HMs without
conventional treatment (table S2) [30,43,44,53,57,71,73,77].
Risk of bias
There is no study with row risk of bias in all the 6 domains and
no study showed low risk of biases in 5 domains. There were 14
studies which showed low risk of bias in the domain of random
sequence generation [21,24,28,34,46–50,55,70,74,78,83]. Alloca-
tion concealment was conducted adequately in 5 studies
[21,24,50,55,78]. 13 studies described about blinding issues
[19,24,28,34,39,40,46,47,51,63,68,70,78]. In 10 studies
[24,25,47,53–55,65,70,75,83], incomplete outcome data such as
numbers of participants who were included, finished treatment
and were dropped out were well described. The selective reporting
domain was not evaluated clearly because we could not locate any
registered protocol for all the included studies. Other risk of bias
such as baseline imbalances were properly described in the
included studies except in 12 studies
[19,22,24,31,36,41,47,49,59,66,72,76].
Figure 1. Flow chart of information for this systematic review.
doi:10.1371/journal.pone.0035695.g001
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the methodological quality of the included studies. No study did
statistical analysis on intention-to-treat basis. In only one study,
sample size calculation was conducted for enough statistical power
[24]. 8 studies referred to the ethical issues such as prior review by
institutional review board [19,24] or written informed consent
from participants [19,21,24,34,55,65,83].
Effects of interventions 1: HM versus placebo [19,34]
2 HMs were compared with placebo in 2 studies [19,34]. Global
improvement of symptoms and total UPDRS score were assessed
for the efficacy of HMs in 2 studies (figure 2) [19,34].
Banisteriopsis caapi extract showed significant improvement in
total UPDRS score 4 hrs after the one time treatment (MD
227.40, [228.19, 226.61]) [19]. 3 months of Guilingpaan
capsule treatment did not show statistically significant difference
in global symptoms (RR 1.30, [0.93, 2.06]) and total UPDRS
score (MD 23.45, [214.99, 8.09]), compared with placebo
control [34].
Effects of interventions 2: HM versus conventional
medicine [30,43,44,53,57,71,73,77]
8 different HMs were tested compared with conventional drug
therapy [30,43,44,53,57,71,73,77]. Global improvement of symp-
toms, Webster scale and total UPDRS score were evaluated in
these studies. Among them, herbal formula Qingxinhuatan tang
only showed statistically significant improvement in global
symptoms (RR 1.33, 95% CI [1.04, 1.72]) compared with
madopar therapy [53]. Herbal formula Kangzhenzhijing capsule
[43], Kanli tang [44] and Ziyinxifeng granule [77] reported
significant improvement in Webster score (MD 21.80, [23.40,
20.20], 22.40, [24.29, 20.51] and 20.50, [20.90, 20.10],
respectively). Herbal formula Zhichanshudu tang showed signif-
icant improvement in total UPDRS score (MD 29.16, [210.68,
27.64]) [73].
Effects of interventions 3: HM plus active drug versus
active drug [20–23,25–27,29,31–33,35–38,41,42,45,48–
50,52,54,55,56,58–62,64–69,72,74–76,79–82]
In 44 studies, HM combined with conventional drug therapy
was compared with conventional drug treatment [20–23,25–
27,29,31–33,35–38,41,42,45,48–50,52,54,55,56,58–62,64–
69,72,74–76,79–82]. Herbal formula Guilingpaan wan was
evaluated in 3 studies [35–37], Xifengdingzhan wan in 3 studies
[61,63,84] and other HMs was used once:
Three months of Guilingpaan wan medication with madopar
showed significant improvement in global symptoms (RR 1.45,
[1.20, 1.77]) [35–37] and total UPDRS score (MD 29.97,
[216.68, 23.25] [35,36] compared with madopar alone.
Xifengdingzhan wan with madopar was administered for 3
months [61,84] and for 1 month [63], respectively. Xifengdingz-
han wan combination therapy improved significantly in global
symptoms (RR 1.47, [1.20, 1.81]) [61,63] and total UPDRS score
(MD 25.41, [26.96, 23.86]) [61,84].
Global improvement of symptoms. 33 studies assessed
global improvement of symptoms. Among them, 3 studies [80–82]
compared the effectiveness of combination treatment on global
symptoms with individualized herbal recipes plus conventional drug
therapy versus single drug therapy, and significant improvement
was observed in 1 study only [79] (RR 2.88, [1.90, 4.34]). The other
studies tested different HMs with conventional drug therapies and
10 herbal recipes including those described earlier, showed
statistically significant improvement in global symptoms [33,35–
37,41,50,52,55,60,61,63,65,79]: Fufangjangzhan wan plus mado-
par (RR 1.40, [1.16, 1.70]) [33], Kanapa granule with madopar
(RR 3.13, [1.79, 5.46]) [41], Pabing formula 2 plus madopar (RR
2.80, [1.15, 6.80]) [50], Peibuganshen recipe plus madopar and
artane (RR1.89, [1.01, 3.55]) [52], Shudipingzhan tang plus Xiewu
capsule plus levodopa (RR 2.27, [1.60, 3.23]) [55], Xifengdinzhan
tang with madopar (RR 1.32, [1.01, 1.72]) [60] and Xifengzhizhan
tang plus madopar (RR 1.50, [1.08, 2.08]) [65].
Total UPDRS score. In total 12 studies
[20,21,35,36,42,45,48,61,65,74,75,84], 10 HM plus conventional
drug therapies were compared with single drug therapy for the
total UPDRS score and among them, 9 HMs including
Guilingpaan wan and Xifengdingzhan wan showed significant
improvement in the score: Bushenyanggan recipe plus levodopa
(MD 25.10, [26.01, 24.19]) [21], Kangzhanning plus madopar
(MD 27.00, [28.88, 25.12]) [42], Lemai granule plus madopar
and Vit B6 (MD 25.40, [210.05, 20.75]) [45], Pabing formula 1
plus madopar (MD 29.04, [217.11, 20.97]) [48], Xifengzhizhan
tang plus madopar (MD 28.89, [213.29, 24.49]), Zhizhan tang
plus madopar (MD 21.30, [22.36, 20.24]) [74] and Zibuganshen
recipe plus madopar, sinemet or artane (MD 210.74, [220.74,
20.74], figure 3) [75].
Webster scale. Webster scale was assessed in 4 studies
[26,52,66,75] and combination therapy showed better effect than
conventional therapy alone in 3 studies: Peibuganshen recipe plus
Figure 2. Herbal medicine versus placebo, total UPDRS score.
doi:10.1371/journal.pone.0035695.g002
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doi:10.1371/journal.pone.0035695.g003
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Yangganxifeng recipe plus madopar (MD 23.00, [24.14,
21.86]) [66] and Zibuganshen recipe plus madopar, sinemet or
artane (MD 22.86, [25.68, 20.04]) [75].
Hoehn & Yahr score. Hoehn & Yahr score was assessed in 2
studies [21,38]. However there was no significant improvement in
these studies.
The dose of anti-Parkinson drug. The dose of anti-
Parkinson drug including levodopa (madopar) or bromocriptine
was compared between combination treatment and conventional
drug therapy groups (figure 4). Mean dose of levodopa (madopar)
was assessed in 10 studies [20,21,55,60,65,67–69,83,84] and
combination therapies decreased the dose significantly in 8 studies:
Bushenpingchan formula (MD 2199.30, [2367.65, 230.95])
[20], Bushenhuoxie recipe (MD 2121.20, [2149.04, 293.36])
[83], Bushenyanggan recipe (MD 280.03, [2113.25, 246.81])
[21], Xifengdingzhan tang (MD 2187.01, [2247.25, 2126.77])
[60], Xifengdingzhan wan (MD 2165.63, [2304.10, 227.16])
[84], Xifengzhizhan tang (MD 2185.24, [2245.56, 2124.92])
[65], Yiguan jian plus dabuyin wan (MD 2187.01, [2257.00,
2117.02]) [67] and Yizhan tang (MD 2120.00, [2148.48,
291.52]) [69].
Non-movement problems. Non-movement problems such
as nausea and constipation were evaluated in several studies. 1
study adopted a validated systemic tool i.e. Parkinson’s disease
non-movement questionnaire (NMSQuest) for non-movement
symptoms: Yiyuan yin plus madopar was compared with single
madopar therapy. However, there was no significant difference
between 2 groups in NMSQest value (MD 21.00, [23.19, 1.19])
[68]. 4 HMs plus conventional drug therapies were tested for the
effect of reducing nausea and vomiting [35–37,55,75,83]. Among
them, 2 HMs showed favorable results: Bushenhuoxie recipe plus
madopar and bromocriptine (RR 0.40, [0.20, 0.81]) [83],
Zibuganshen recipe plus madopar and sinemet or artane (RR
0.36, [0.14, 0.94]) [75].
7 herbal remedies with anti-Parkinson drugs were evaluated on
constipation in PD patients [29,36,42,55,68,75,83] and 3 recipes
showed better results: Bushenhuoxie recipe plus madopar and
bromocriptine (RR 0.11, [0.03, 0.46]) [83], Dingzhen tang_2 plus
conventional treatment (RR 0.48, [0.29, 0.78]) [29] and
Kangzhanning plus madopar (RR 0.50, [0.28, 0.88]) [42].
Anti-depressive effect. Anti-depressive effect of combina-
tion therapy in PD patients was tested in 1 study. Compared with
paroxetine treatment alone, Chaihushugan san plus paroxetine
showed significant improvement in HAM-D score (MD 24.10,
[25.17, 23.03]) after 8 weeks of treatment with low adverse event
rate (RR 0.48, [0.31, 0.74]) [25].
Total adverse event rate. Total adverse event rate was
assessed in 8 studies [25,31,38,45,54,56,61,84] and 5 studies (4
HMs) reported significantly low rate of adverse event: Chaihush-
ugan san plus paroxetine (RR 0.48, [0.31, 0.74]) [25], Dingzhen
tang_4 plus madopar and artane (RR 0.39, [0.18, 0.83]) [31],
Ruogantongluo tang plus madopar (RR 0.36, [0.14, 0.89]) [45]
and Xifengdingzhan wan plus madopar (RR 0.41, [0.21, 0.80])
[61,84].
Effects of interventions 4: HM plus active drug versus
placebo plus active drug
[11,24,28,34,39,40,46,47,51,63,70,78]
12 studies compared the effect of HM plus active drug and those
of placebo plus active drug [11,24,28,34,39,40,46,47,51,63,70,78].
In 8 studies, global improvement of symptoms was compared
between HMs and placebo controls both of which were combined
with active drugs [28,34,39,46,47,51,63,78]. Among them, signif-
icant improvement was observed in 5 studies: Jiaweidadingfeng
zhu plus madopar (RR 3.83, [1.82, 8.05]) [39], Naokangning
capsule plus madopar (RR 1.53, [1.02, 2.31]) [46], Nuzhenyan-
gyin granule plus madopar and artane (RR 1.53, [1.09, 2.16])
[47], Pabing formula 3 plus madopar (RR 2.60, [1.06, 6.39]) [51]
and Xifengdingzhan wan plus madopar (RR 1.44, [1.11, 1.87])
[63].
Total UPDRS score was evaluated in 5 studies [29,46,63,70,78]
and 2 HMs showed significant improvement comparing with
placebo plus active drug treatment: Naokangning capsule plus
madopar (MD 26.00, [211.24, 20.76]) [46] and Xifengdingzhan
wan plus madopar (MD 25.10, [26.57, 23.63]) [63].
SF-36 questionnaires were assessed for evaluating quality of life
for PD patients in 1 study [46]. Compared with placebo plus active
treatment, Naokangning capsule plus madopar improved signif-
icantly in the subsections for the physical functioning (58.74
(14.16) in Naokangning plus madopar group, 46.83 (16.43) in
placebo plus madopar, P,0.05), social functioning (77.26 (27.57),
64.63 (20.39), P,0.05), role limitations due to physical health
(68.59 (16.33), 49.62 (18.25), P,0.05) and vitality (67.21 (18.05),
48.92 (23.49), P,0.05) [46].
Discussion
Among the included 64 RCTs, 59 herbal preparations were
used for treating PD. Majority of studies were conducted in China
and HMs were composed of multiple herbs in almost all studies.
Only 5 HMs were used several times but other studies were
conducted with high heterogeneities in herbal preparations and
study design. HMs was used with conventional drugs concomi-
tantly in majority of the included studies. Efficacy of HMs was
tested in 2 studies by comparing with placebo control. Banister-
iopsis caapi extract showed short-term effect in improving UPDRS
score but 3 months of Guilingpaan capsule medication did not
have statistically significant differences in PD symptoms [19,34].
HMs were directly compared with conventional drug therapy in 8
studies and only Qingxinhuatan tang improved general symptoms
of PD significantly in one study [53]. Combination therapy with
HMs and anti-Parkinson drugs showed significant improvement in
the assessment of general symptoms and UPDRS scores and
decrease in the dose of anti-Parkinson drugs generally. Adverse
events rate also decreased significantly in combination therapies.
Compared with the previous systematic review in 2006 [85], the
number of conducted RCTs increased steeply from 9 to 64.
However, as with before, the result of this systematic review
cannot suggest conclusive evidence of HMs because of several
limitations the included studies had. Firstly, only a small number
of preparations were used twice or more and most of the HMs
were tested only once. A huge heterogeneity in the herbal
composition, drug formulation, dose, duration, combined therapy
and control interventions was observed between the studies, which
were the main obstacles to estimate the general effect size of herbal
remedies. Secondly, significant improvement in the methodolog-
ical qualities of included studies was not observed compared with
the previous review. As pointed out before, most of the studies did
not report about allocation concealment process. Incomplete
outcome data including drop out were not reported in 53 studies.
Because any pre-registered protocols of included trials were not
located, selective outcome reporting could not be judged clearly in
all the studies. Only one studies adopted ITT analysis for statistics.
In this review, except 2 studies, all the searched studies were
conducted in China. There have been debates about the results of
clinical trials in some countries including China, which may be
originated from their methodological flaws and publication bias
Herbal Medicines for Parkinson’s Disease
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treatment effect than rigorous studies [87]. Thirdly all the included
studies tested only small sample size without proper power
calculation. Generally studies with small sample may not detect
clinically important difference between interventions [88]. Among
the included studies in this review, some HMs did not show
statistically significant effect in favor of herbal preparations
compared with placebo or conventional treatment which may be
originated from their insufficient sample size. Fourthly there may
be a possibility of publication bias in this review. We checked
funnel plots of two key outcomes i.e. total UPDRS scores and
mean dose of levodopa in the comparison of HM plus active drug
and active drug only. Both of the funnel plots appeared
asymmetric, which might be originated from publication bias or
poor methodological qualities of the included studies (figure 5 and
6).
In these points, the findings of this systematic review should be
interpreted carefully.
Even with several limitations, this review also has strength as
well. We did comprehensive search regardless of language and
publication types to locate every possible RCT. We failed to
suggest overall estimates of treatment effects on PD but herbal
recipes and estimates of effect measures on the separate outcomes
for individual HMs were presented to provide information in
detail, which may be available to suggest a basic source for judging
the possibility of treating PD and after all may offer a principle
data to find out new drug candidates for PD [89].
There are several issues on the HMs for the treatment of PD,
which should be discussed more. We found that herbal recipes
were generally used as adjuvant treatments to conventional drug
therapy which may contribute to improve the PD symptoms and
to decrease dose of anti-Parkinson drugs and adverse events rate.
Many PD patients experience dyskinesia and symptom fluctuation
from the long-term treatment with levodopa [90]. Combination
therapy with some HMs showed significant or marginal effect in
reducing complications of levodopa (UPDRS IV) [41]. The dose
of levodopa is also one of the important clinical considerations
because PD needs lifelong treatment generally. Considering
wearing-off symptoms, it would be helpful for both patients and
clinicians to reduce dose of levodopa for managing PD symptoms
[1]. In this point, HM may be considered as a good adjunctive
treatment to conventional drugs for PD. On the contrary, HMs for
treating PD needs to equip standardized criteria for use to ensure
the good quality of the products. It includes the problems related
to the original species of individual herbs, chemical compositions
and indexes, preparations and indications for herbal products.
Chinese formulas were composed of many herbs and there were a
wide heterogeneity in the HMs between the studies included in
this review. In this situation, standardization of natural products
used in the clinical trials is one of the most necessary factors for
demonstrating good reproducibility of the research result in real
clinical practices. Pharmacological researches including in vivo
and in vitro studies should be promoted to support biological
mechanism of herbal products as well. Adverse effects (AE)
relevant to herbal recipes also need to be described clearly. AEs of
the drugs for PD are well documented and are frequently reported
of high occurrence rate in conventional medicine [1]. For
example, in one study, dyskinesia was experienced in up to 40%
of PD patients after 4 to 6 years of levodopa treatment [90]. In this
review, occurrence of adverse events was relatively low in the
combination therapies. This result may be originated from the fact
that observation periods of the included studies were relatively
short. Safety issues need to be one of the primary outcomes and
clearly be described in future trials with long term observational
period.
Future clinical trials of HMs on PD need to improve
methodological quality to evaluate clinical benefit and harm
properly. Random sequence generation and double blinding
should be ensured in study design and results need to be reported
well according to the CONSORT statement [91]. Protocol
registration before start of clinical trials is also important to
guarantee the transparency of the study finding through avoiding
selective outcome reporting and publication bias [92]. Along with
trials for efficacy in which single HM is compared with placebo
control, comparative effectiveness studies using combination
therapy with conventional drug therapies also need to be
conducted to reflect clinical situation as it is.
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